SCHEMBL17119648

SCHEMBL17119648

OCc1cnc(Cl)cc1Nc1cccnc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ KMT2A Q03164 5/20 0.40
▸ MEN1 O00255 4/20 0.40
▸ MAPT P10636 2/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ RAD52 P43351 1/20 0.38
▸ CCNK O75909 1/20 0.38
▸ CCNA2 P20248 1/20 0.38
▸ CDK2 P24941 1/20 0.38
▸ CCND3 P30281 1/20 0.38
▸ CDK9 P50750 1/20 0.38
▸ CDK6 Q00534 1/20 0.38
▸ NOTUM Q6P988 1/20 0.38
▸ HTT P42858 2/20 0.38
▸ KIF11 P52732 1/20 0.38
▸ RECQL P46063 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4421499 0.85 ALDH1A1 (0.39) KDM4EL3MBTL1KMT2AMEN1MAPT
SCHEMBL17119641 0.84 ADRA2A (0.42) KDM4EL3MBTL1KMT2AMEN1LMNA
SCHEMBL17119646 0.77 GRIK1 (0.52) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL17119647 0.76 CCNK (0.41) KDM4ERAB9ANPC1L3MBTL1KMT2A
SCHEMBL1231857 0.75 KIF11 (0.50) RAB9ANPC1L3MBTL1MAPTALDH1A1
SCHEMBL18748195 0.73 TP53 (0.47) KDM4ERAB9ANPC1MAPTALDH1A1
SCHEMBL1521667 0.71 PDXK (0.38) KDM4ERAB9ANPC1KMT2AMEN1
SCHEMBL29765350 0.71 PDXK (0.38) KDM4ERAB9ANPC1KMT2AMEN1
SCHEMBL22129304 0.69 KDM4E (0.49) KDM4EL3MBTL1MAPTALDH1A1
SCHEMBL29743231 0.69 KDM4E (0.49) KDM4EL3MBTL1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9714247-B2 Multiple kinase pathway inhibitors TOLERO PHARMACEUTICALS, INC. (US) 2017-07-25 — — US disclosed
US-9714247-B2 Multiple kinase pathway inhibitors TOLERO PHARMACEUTICALS, INC. (US) 2017-07-25 — — US disclosed
US-20170107215-A1 MULTIPLE KINASE PATHWAY INHIBITORS SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-04-20 — — US disclosed
US-20170107215-A1 MULTIPLE KINASE PATHWAY INHIBITORS SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-04-20 — — US disclosed
US-9493454-B2 Multiple kinase pathway inhibitors TOLERO PHARMACEUTICALS, INC. (US) 2016-11-15 — — US disclosed
US-9493454-B2 Multiple kinase pathway inhibitors TOLERO PHARMACEUTICALS, INC. (US) 2016-11-15 — — US disclosed
US-20150266870-A1 MULTIPLE KINASE PATHWAY INHIBITORS MANNKIND CORPORATION 2015-09-24 — — US disclosed
US-20150266870-A1 MULTIPLE KINASE PATHWAY INHIBITORS MANNKIND CORPORATION 2015-09-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266870-A1 MULTIPLE KINASE PATHWAY INHIBITORS MAP3K6, MAP3K2, MAP3K1 KDM4E 2130/4885RAB9A 2162/4885NPC1 2969/4885
US-20170107215-A1 MULTIPLE KINASE PATHWAY INHIBITORS MAP3K6, MAP3K2, MAP3K1 KDM4E 2130/4885RAB9A 2162/4885NPC1 2969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback